1. |
Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment[J]. Surv Ophthalmol, 2009, 54(1): 1-32. DOI: 10.1016/j.survophthal.2008.10.001.
|
2. |
Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase Ⅲ trials: RISE and RIDE[J]. Ophthalmology, 2013, 120(10): 2013-2022. DOI: 10.1016/j.ophtha.2013.02.034.
|
3. |
Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema[J]. Ophthalmology, 2014, 121(11): 2247-2254. DOI: 10.1016/j.ophtha.2014.05.006.
|
4. |
Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11): 2376-2385. DOI: 10.1016/j.ophtha.2016.07.032.
|
5. |
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase Ⅲ randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4): 789-801. DOI: 10.1016/j.ophtha.2011.12.039.
|
6. |
Yanagida Y, Ueta T. Systemic safety of ranibizumab for diabetic macular edema: meta-analysis of randomized trials[J]. Retina, 2014, 34(4): 629-635. DOI: 10.1097/IAE.0000000000000116.
|
7. |
Morizane Y, Kimura S, Hosokawa M, et al. Planned foveal detachment technique for the resolution of diffuse diabetic macular edema[J]. Jpn J Ophthalmol, 2015, 59(5): 279-287. DOI: 10.1007/s10384-015-0390-4.
|
8. |
Frank RN. Diabetic retinopathy[J]. N Engl J Med, 2004, 350(1): 48-58. DOI: 10.1056/NEJMra021678.
|
9. |
Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets[J]. Ophthalmology, 2015, 122(7): 1375-1394. DOI: 10.1016/j.ophtha.2015.03.024.
|
10. |
Terasaki H, Ogura Y, Kitano S, et al. Management of diabetic macular edema in Japan: a review and expert opinion[J]. Jpn J Ophthalmol, 2018, 62(1): 1-23. DOI: 10.1007/s10384-017-0537-6.
|
11. |
Urias EA, Urias GA, Monickaraj F, et al. Novel therapeutic targets in diabetic macular edema: beyond VEGF[J]. Vision Res, 2017, 139(10): 221-227. DOI: 10.1016/j.visres.2017.06.015.
|
12. |
Ghassemi F, Bazvand F, Roohipoor R, et al. Outcomes of vitrectomy, membranectomy and internal limiting membrane peeling in patients with refractory diabetic macular edema and non-tractional epiretinal membrane[J]. J Curr Ophthalmol, 2016, 28(4): 199-205. DOI: 10.1016/j.joco.2016.08.006.
|
13. |
Yamamoto T, Hitani K, Tsukahara I, et al. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema[J]. Am J Ophthalmol, 2003, 135(1): 14-19. DOI: 10.1016/S0002-9394(02)01819-6.
|
14. |
Yanyali A, Horozoglu F, Celik E, et al. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema[J]. Retina, 2007, 27(5): 557-566. DOI: 10.1097/01.iae.0000249390.61854.d5.
|
15. |
Abdel Hadi AM. Evaluation of vitrectomy with planned foveal detachment as surgical treatment for refractory diabetic macular edema with or without vitreomacular interface abnormality[J/OL]. J Ophthalmol, 2018, 2018: 9246384[2018-05-07]. https://doi.org/10.1155/2018/9246384. DOI: 10.1155/2018/9246384.
|
16. |
Toshima S, Morizane Y, Kimura S, et al. Planned foveal detachment technique for the resolution of diabetic macular edema resistant to anti–vascular endothelial growth factor therapy[J]. Retina, 2019, 39 Suppl 1: S162-168. DOI: 10.1097/IAE.0000000000001771.
|
17. |
Michalewska Z, Stewart MW, Landers MB 3rd, et al. Vitrectomy in the management of diabetic macular edema in treatment-naïve patients[J]. Can J Ophthalmol, 2018, 53(4): 402-407. DOI: 10.1016/j.jcjo.2017.10.011.
|